Teva Pharmaceutical Industries Limited filings document material events, operating and financial results, capital-structure matters, governance, and shareholder voting for the Israel-based pharmaceutical issuer. Its 8-K reports include results announcements, conference-related outlook disclosures, and material definitive agreements, including amendments to a senior unsecured sustainability-linked revolving credit facility.
Teva's proxy materials cover annual meeting procedures, shareholder proposals, governance matters, and annual consolidated financial statements. The filing record also identifies the company's American Depositary Shares, each representing one ordinary share, as securities registered for trading under TEVA on the New York Stock Exchange.
Mark Sabag, TEVA’s Executive Vice President, International Markets Commercial, exercised 46,000 stock options on November 5, 2026, at an exercise price of $34.90 per share, acquiring 46,000 ordinary shares. He sold those shares the same day at a weighted average price of $41.9289 per share; the reported sale prices ranged from $41.81 to $42.08. The reported post-transaction stock-option balance was 44,710 options.
Dov Bergwerk, TEVA’s interim chief legal officer, exercised options for 17,505 ordinary shares at $34.70 per share and 8,755 ordinary shares at $28.98 per share on November 4, 2026. He acquired the corresponding shares and sold the same quantities that day, each sale at $41.72 per share. No Rule 10b5-1 plan is reported.
TEVA officer Mark Sabag, executive vice president of International Markets Commercial, reported a proposed sale of 46,000 ordinary shares with an aggregate market value of $1,928,728.30. The transaction is described as a stock option exercise and sale for compensation, with an approximate sale date of November 5, 2026, and Citigroup Global Markets Inc. named as broker.
Teva Pharmaceutical Industries Ltd. (TEVA) is the issuer named in a Rule 144 notice in which Senior VP, General Counsel and Corporate Secretary Dov Bergwerk reports a proposed sale of 26,260 ordinary shares through a stock option exercise and sale transaction dated November 4, 2026. The notice lists an indicative market price of $41.72 per share, an aggregate market value of $1,095,567.20, and Citigroup Global Markets, Inc. as broker.
TEVA Pharmaceutical Industries Limited reported third-quarter 2026 net income attributable to Teva of $233 million, versus $433 million a year earlier; for the first nine months, it was $26 million versus $930 million. Net revenues were $4.395 billion for the quarter and $12.519 billion for nine months. Operating cash flow for the first nine months was $612 million, compared with $491 million in 2025.
Cash and cash equivalents were $4.085 billion at September 30, 2026, while senior notes and loans were $12.680 billion. Teva completed its Emalex Biosciences acquisition on June 10, paying approximately $700 million to the former shareholders. The FDA accepted Teva’s ecopipam NDA and granted Priority Review on August 18, 2026.
Teva Pharmaceutical Industries Ltd. (TEVA) reported third-quarter 2026 revenue of $4.395 billion, down 2% year over year, as global generics revenue fell 16% in local-currency terms, primarily due to U.S. competition for lenalidomide capsules. AUSTEDO, AJOVY and UZEDY generated approximately $1.1 billion combined, up 33% in local currency. Gross margin was 55.5%, versus 51.4%; non-GAAP gross margin was 58.7%, up 345 basis points.
GAAP net income attributable to Teva was $233 million and diluted EPS was $0.20, versus $433 million and $0.37 a year earlier. Non-GAAP net income attributable to Teva was $1.013 billion and non-GAAP diluted EPS was $0.86, up 10%; adjusted EBITDA was $1.496 billion, up 7%. Operating cash flow was $241 million, versus $369 million, while free cash flow was $495 million, down 4%.
Teva raised its 2026 revenue outlook to $16.7–$17.0 billion from $16.5–$16.85 billion, and raised outlooks for AUSTEDO to $2.55–$2.65 billion, AJOVY to $930–$960 million, and UZEDY to $290–$310 million. The FDA approved WELTRUZA in October 2026; Teva expects U.S. availability in the coming weeks.
TEVA Pharmaceutical Industries Ltd. shares: Harel Insurance Investments & Financial Services Ltd. reported beneficial ownership of 70,418,201 ordinary shares, or 6.0% of the class. Harel reported shared voting power over 69,390,266 shares and shared dispositive power over 70,418,201 shares, with no sole voting or dispositive power.
The reported 6.0% is based on 1,165,296,084 TEVA ordinary shares issued and outstanding as of June 30, 2026. Harel said the reported amount should not be construed as an admission that it beneficially owns more than 1,015,197 shares, which it identified as held for its own account; other reported shares include member and third-party client holdings managed by subsidiaries.
Teva Pharmaceutical Industries Limited elected Dr. David J. Brailer to its Board of Directors, effective November 3, 2026, until Teva’s 2027 annual meeting of shareholders. The Board determined that he qualifies as an independent director under New York Stock Exchange listing rules.
Brailer will receive the same compensation as Teva’s other non-executive directors, as described in the company’s March 31, 2026 definitive proxy statement. His roles include Chairman and Chief Executive Officer of medem.ai since 2024, Founder and Executive Chairman of Health Evolution since 2010, and Chief Health Officer of The Cigna Group from 2022 to 2026. Teva stated that no arrangements or understandings led to his election.
TEVA interim chief legal officer Dov Bergwerk reported direct holdings of 11,943 ordinary shares as of September 29, 2026. Reported holdings also include options covering 17,505 shares at $34.70, expiring March 3, 2027, and 8,755 shares at $28.98, expiring May 24, 2027. His restricted share unit balances are 16,742, 16,742, 10,719, 13,673 and 7,771 units; each represents a contingent right to one ordinary share or its cash value, at the compensation committee’s option.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported that Interim Chief Legal Officer Brian Savage exercised stock options for 4,503 Ordinary Shares on September 18, 2026 at an exercise price of $34.70 per share and then sold a total of 7,342 Ordinary Shares in market transactions that day.
The exercised options were originally granted on March 3, 2017 and are now fully exercised, leaving no options from this grant outstanding; no Rule 10b5-1 trading plan is indicated for these transactions.